CareCost Vials
2 × 300 mg
1 billing unit = 1 mg
600 mg maintenance dose → 600 billing units
J2350 · ocrelizumab
300 mg/10 mL single-dose vial · JZ on the 300 mg and 600 mg doses
Calculate this patient's units ↓300 mg, then 300 mg 2 weeks later, then 600 mg every 6 months thereafter
This Ocrevus claim carries straight into Claim Check.
Claim Check builds the whole visit — J2350 units, the administration line, the modifiers and the Medicare allowed amount — and prices it against your payer's rate. The estimate turns the same visit into what the patient owes.
Free · No credit card · No sales call
Patient owes, 600 mg
Change the payer and the estimate re-prices against that payer's own published rate. The result is a good faith estimate for the patient.
J2350 bills 1 unit per 1 mg: ordered dose ÷ 1 mg = billing units. Each 300 mg initial infusion is 300 units, and the 600 mg maintenance dose is 600 units. Ocrevus starts with two equal initial infusions two weeks apart, then settles into a flat maintenance dose every 6 months; there is no multi-step titration.
Ocrevus ships as a 300 mg/10 mL single-dose vial. The 300 mg initial infusions each draw one vial with nothing left over, and the 600 mg maintenance dose draws two vials with nothing left over, so JZ is the modifier on all three of those doses. The exception is the pediatric 150 mg initial dose (25 kg to under 35 kg), which draws a whole 300 mg vial but administers only half of it, the one scenario on an Ocrevus claim where JW applies.
Medicare pays $60.689 per mg (ASP+6%), effective for claims in Q4 2026: $36,413.40 for the
600-unit maintenance dose above.
A standard 3.5-hour maintenance visit puts four lines on the claim:
| Line | Code | Units | Modifier | Allowed |
|---|---|---|---|---|
| Drug | J2350 | 600 | JZ | $36,413.40 |
| Administration, first hour | 96413 | 1 | N/A | $133.27 |
| Administration, additional hours | 96415 | 2 | N/A | $56.78 |
| Total allowed | $36,603.45 | |||
| Infusion | Dose | Billing units | Vials | Modifier |
|---|---|---|---|---|
| Initial infusion 1 | 300 mg | 300 | 1 × 300 mg | JZ |
| Initial infusion 2 (2 weeks later) | 300 mg | 300 | 1 × 300 mg | JZ |
| Maintenance (every 6 months) | 600 mg | 600 | 2 × 300 mg | JZ |
Each row above is a whole number of 300 mg vials, so JZ applies on every adult infusion and JW never comes up. Pediatric patients 10 years and older who weigh 35 kg or more follow the same schedule. Pediatric patients weighing 25 kg to under 35 kg take half doses: 150 mg, then 150 mg two weeks later, then 300 mg maintenance every 6 months. The 300 mg pediatric maintenance dose draws one vial with nothing left over (JZ), but each 150 mg initial dose draws a whole 300 mg vial and administers only half of it. 150 units go on the claim as administered, and the other 150 units go on a separate line with JW.
JZ: no discarded drug from a single-dose container. JW: discarded drug from a single-dose container, reported on its own claim line. One of the two is required on every J2350 claim per CMS's July 1, 2023 single-dose container policy.
J2350 × 300 JZ · 96413 × 1 · 96415 × 1.
J2350 × 600 JZ · 96413 × 1 · 96415 × 2. The two initial
infusions and the maintenance dose all work out the same way. JZ is the modifier, and JW never applies.
J2350 × 150 (administered) plus J2350 × 150 JW (discarded) on the
same date of service. Every other Ocrevus dose draws a whole number of vials with nothing left over.
Ocrelizumab is a CD20-directed cytolytic antibody, billed with the chemotherapy and complex-biologic administration codes: 96413 for the first hour, 96415 for each additional hour. Which codes apply depends on the infusion:
| Infusion | Duration | Codes |
|---|---|---|
| Initial infusion (each, 300 mg) | 2.5 hours or longer | 96413 × 1, 96415 × 1 |
| Maintenance, Option 1 (600 mg) | 3.5 hours or longer | 96413 × 1, 96415 × 2 |
| Maintenance, Option 2 (600 mg, no prior serious infusion reaction) | about 2 hours | 96413 × 1, 96415 × 1 |
Option 2 is available only after a patient has had no prior serious infusion reaction with any Ocrevus infusion; otherwise Option 1's 3.5-hour infusion is the default. A minority of payers still require the 96365/96366 therapeutic-infusion family instead of 96413/96415 for ocrelizumab. Confirm the payer's position before the first claim.
The MUE for J2350 is 600 units per day, exactly the 600 mg maintenance dose. A claim billed at the maintenance dose sits right at that limit; a claim line above 600 units for a single day fails the MUE edit. The 300-unit initial infusions and the pediatric 150-unit and 300-unit doses all clear the edit, but nothing above 600 does.
Ocrevus ships in one size: a 300 mg/10 mL (30 mg/mL) single-dose vial, refrigerated. J2350 (“Injection, ocrelizumab, 1 mg”) is the HCPCS code for the infused product. Ocrevus Zunovo (J2351) is the subcutaneous sibling of the same molecule: a fixed 920 mg dose billed under a separate code, with the administration billed as 96401 or 96372 depending on the payer, and never interchangeable with J2350. See the FDA Ocrevus label (BLA 761053) for full dosing and administration instructions, or the current Medicare rate for J2350 →.
600 billing units. J2350 bills 1 unit per 1 mg, and 600 mg is the maintenance dose Ocrevus reaches every 6 months after the two initial infusions.
300 units for each of the two 300 mg initial infusions, given two weeks apart, each drawn from one 300 mg vial and billed with JZ.
JZ on every adult dose and on the pediatric 300 mg maintenance dose, because each is a whole number of 300 mg vials. JW applies only to the pediatric 150 mg initial dose (25 kg to under 35 kg), which draws a whole 300 mg vial for a half dose and reports the other 150 mg as discarded.
600 units per day for J2350, exactly the 600 mg maintenance dose. A claim billed at the maintenance dose sits right at that limit; a claim line above it fails the edit.
Per 1 mg. J2350 is defined as 1 mg per billing unit, so a 600 mg dose is 600 units, not 300.
Data current: pricing Q4 2026 · payer policies Aug 2026
Sources: CMS ASP pricing files (Q4 2026); FDA-approved prescribing information (OCREVUS label, DailyMed, BLA 761053); CMS single-dose container JW/JZ policy (effective July 1, 2023); CMS NCCI MUE table (practitioner services, 2026 Q3); CPT codebook administration-code guidance; 27 commercial payer medical policies in the ocrelizumab Clearance corpus.
Reviewed September 21, 2026 by Erin Rose, CareCost Estimate founder. Methodology →